An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-Old Adults
Phase of Trial: Phase II
Latest Information Update: 29 May 2018
At a glance
- Drugs JNJ 64400141 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Janssen Vaccines and Prevention B.V
- 22 May 2018 Planned primary completion date changed from 22 May 2018 to 10 Jul 2018.
- 04 Apr 2018 Planned primary completion date changed from 30 Mar 2018 to 22 May 2018.
- 31 Jan 2018 Planned End Date changed from 31 Aug 2018 to 30 Oct 2018.